van TulderMW, TourayT, FurlanAD, et al.: Muscle relaxants for nonspecific low back pain: A systematic review within the framework of the cochrane collaboration. Spine, 2003; 28:1978–1992.
2.
SeeS, GinzburgR: Choosing a skeletal muscle relaxant. Am Fam Physician, 2008; 78:365–370.
3.
SpenceMM, ShinPJ, LeeEA, GibbsNE: Risk of injury associated with skeletal muscle relaxant use in older adults. Ann Pharamcother, 2013:47:993–998.
ChouR, PetersonK, HelfandM: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: A systematic review. J Pain Symptom Manage, 2004; 28:140–175.
6.
BrarSP, SmithMB, NelsonLM, et al.: Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehabil, 1991; 72:186–189.
7.
SmithC, BirnbaumG, CarterJL, et al.: Tizanidine treatment of spascticity caused by multiple sclerosis: Results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology, 1994; 44(11 Supp 9): S34–S42;discussion S42–S43.
8.
HoogstratenMC, van der PloegRJ, vd BurgW, et al.: Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurol Scand, 1988; 77:224–230.
9.
FrommGH: Baclofen as an adjuvant analgesic. J Pain Symptom Manage, 1994; 9:500–509.
10.
AddoloratoG, LeggioL, FerrulliA, et al.: Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study. Lancet, 2007; 370:1915–1922.
